FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::FIRST QUARTER RESULTS

Issuer & Securities Issuer/ Manager **GOLDEN AGRI-RESOURCES LTD** Securities GOLDEN AGRI-RESOURCES LTD - MU0117U00026 - E5H **Stapled Security** No **Announcement Details Announcement Title** Financial Statements and Related Announcement Date &Time of Broadcast 14-May-2019 07:04:16 Status New Announcement Sub Title First Quarter Results **Announcement Reference** SG190514OTHRCDTG Submitted By (Co./ Ind. Name) Kimberley Lye Chor Mei Designation Director, Corporate Secretarial Description (Please provide a detailed description of the event in the box below - Refer to the Online help for the format) Golden Agri-Resources Ltd has released its unaudited financial results for the first quarter ended 31 March 2019. Please refer to the following attachments in relation thereto: (1) Unaudited consolidated financial statements for the first quarter ended 31 March 2019; (2) Press Release; and (3) Interim Performance Presentation. **Additional Details** For Financial Period Ended 31/03/2019 **Attachments** GAR%201Q2019%20Results-Final.pdf GAR%201Q2019%20Press%20Release.pdf GAR-1Q2019%20Financial%20Results%20Presentation.pdf

Total size =1512K MB



GOLDEN AGRI-RESOURCES LTD

.......

First Quarter Financial Statement And Dividend Announcement

 ${\tt randala} {\tt ana} {\tt ana}$

FINANCIAL HIGHLIGHTS

| | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> | Change <u>%</u> |
|--|------------------------------------|------------------------------------|--------------------|
| Revenue | 1,617,295 | 1,816,172 | (11.0) |
| Gross Profit | 192,762 | 248,120 | (22.3) |
| EBITDA ¹ | 120,639 | 121,134 | (0.4) |
| Underlying profit ² | 11,768 | 24,788 | (52.5) |
| Underlying profit per share (USD cents) | 0.09 | 0.19 | (52.5) |
| Net profit attributable to owners of the Company | 18,314 | 11,851 | 54.5 |

Notes

- (1) Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net loss from changes in fair value of biological assets, foreign exchange gain/(loss) and exceptional item.
- (2) Net profit attributable to owners of the Company excluding net effect of net gain or loss from changes in fair value of biological assets and depreciation of bearer plants, exceptional item and other non-operating items (foreign exchange gain or loss, net tax impact from tax-based asset revaluations, and other deferred tax income or expense).

PART I - INFORMATION REQUIRED FOR QUARTERLY (Q1, Q2 & Q3), HALF-YEAR AND FULL YEAR ANNOUNCEMENTS

1(a) An income statement and statement of comprehensive income for the group together with a comparative statement for the corresponding period of the immediately preceding financial year

UNAUDITED CONSOLIDATED INCOME STATEMENT FOR THE PERIOD ENDED 31 MARCH 2019

| FOR THE PERIOD ENDED 31 MARCH 2019 | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> | Change <u>%</u> |
|--|------------------------------------|------------------------------------|--------------------|
| Revenue | 1,617,295 | 1,816,172 | (11.0) |
| Cost of sales | (1,424,533) | (1,568,052) | (9.2) |
| Gross profit | 192,762 | 248,120 | (22.3) |
| Operating expenses | | | |
| Selling expenses | (90,532) | (131,280) | (31.0) |
| General and administrative expenses | (70,566) | (76,012) | (7.2) |
| Total operating expenses | (161,098) | (207,292) | (22.3) |
| Operating profit | 31,664 | 40,828 | (22.4) |
| Other income/(expenses) | | | |
| Financial income | 5,800 | 9,238 | (37.2) |
| Financial expenses | (41,823) | (37,218) | 12.4 |
| Share of results of associated companies, net of tax | 2,931 | (112) | n.m. |
| Share of results of joint ventures, net of tax | (2,929) | (3,011) | (2.7) |
| Foreign exchange gain | 18,207 | 5,073 | 258.9 |
| Other operating income | 8,447 | 2,634 | 220.7 |
| | (9,367) | (23,396) | (60.0) |
| Exceptional item | | | |
| Gain on disposal of a subsidiary | 11,449 | | n.m. |
| Profit before tax | 33,746 | 17,432 | 93.6 |
| Tax | (7,624) | (4,002) | 90.5 |
| Profit for the period | 26,122 | 13,430 | 94.5 |
| Attributable to: | | | |
| Owners of the Company | 18,314 | 11,851 | 54.5 |
| Non-controlling interests | 7,808 | 1,579 | 394.5 |
| | 26,122 | 13,430 | 94.5 |
| | | | |

Note:

(1) n.m. – not meaningful.

UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 31 MARCH 2019

| | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> |
|--|------------------------------------|------------------------------------|
| Profit for the period | 26,122 | 13,430 |
| Other comprehensive income/(loss): | | |
| Items that will not be reclassified subsequently to profit or loss: | | |
| Share of other comprehensive income/(loss) of a joint venture Changes in fair value of financial assets at fair value through other | 1 | (44) |
| comprehensive income | 7,285 | - |
| Items that may be reclassified subsequently to profit or loss: | | |
| Foreign currency translation differences on consolidation | 3,008 | 2,107 |
| Share of other comprehensive income/(loss) of: | | |
| Joint ventures | 380 | (596) |
| Associates | (763) | - |
| Changes in fair value of available-for-sale financial assets | - | (1,469) |
| Other comprehensive income/(loss), net of tax | 9,911 | (2) |
| Total comprehensive income for the period, net of tax | 36,033 | 13,428 |
| Total comprehensive income attributable to: | | |
| Owners of the Company | 27,574 | 12,298 |
| Non-controlling interests | 8,459 | 1,130 |
| <u>.</u> | 36,033 | 13,428 |

ADDITIONAL INFORMATION

Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain/(loss) from changes in fair value of biological assets, foreign exchange gain and exceptional item ("EBITDA")

| | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> | Change <u>%</u> |
|---|------------------------------------|------------------------------------|--------------------|
| Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain/(loss) from changes in fair value of biological assets, foreign exchange gain and exceptional item ("EBITDA") | 120,639 | 121,134 | (0.4) |
| Interest on borrowings | (41,275) | (36,533) | 13.0 |
| Depreciation and amortisation | (76,295) | (71,431) | 6.8 |
| Net gain/(loss) from changes in fair value of biological assets | 1,021 | (811) | n.m. |
| Foreign exchange gain | 18,207 | 5,073 | 258.9 |
| Exceptional item | 11,449 | | n.m. |
| Profit before tax | 33,746 | 17,432 | 93.6 |

Note:

(1) n.m. – not meaningful.

1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year

UNAUDITED STATEMENTS OF FINANCIAL POSITION

| | Group | | Company | | |
|--|---------------------------------------|--|---------------------------------------|--|--|
| | As at 31/3/2019 <u>US\$'000</u> | As at 31/12/2018 <u>US\$'000</u> | As at 31/3/2019 <u>US\$'000</u> | As at 31/12/2018 <u>US\$'000</u> | |
| Assets | | | | | |
| Current Assets | | | | | |
| Cash and cash equivalents | 221,888 | 192,766 | 88 | 88 | |
| Short-term investments | 340,455 | 351,855 | - | - | |
| Trade receivables | 492,068 | 533,692 | - | - | |
| Other current assets (note (a)) | 799,236 | 804,835 | 81 | 11 | |
| Inventories | 961,040 | 1,002,350 | <u> </u> | | |
| | 2,814,687 | 2,885,498 | 169 | 99 | |
| Non-Current Assets Long-term receivables and assets (note (b)) | 303,393 | 323,525 | _ | _ | |
| Long-term investments | 1,202,363 | 1,077,772 | 185,065 | 175,065 | |
| Subsidiary companies | - | - | 3,431,433 | 3,431,355 | |
| Associated companies | 19,642 | 17,546 | - | - | |
| Joint ventures | 85,893 | 88,723 | - | - | |
| Investment properties | 113 | 112 | - | _ | |
| Property, plant and equipment | 2,628,536 | 2,624,108 | - | - | |
| Bearer plants | 1,075,647 | 1,092,166 | - | - | |
| Right-of-use assets | 41,870 | - | - | - | |
| Deferred tax assets | 241,205 | 244,023 | - | - | |
| Intangible assets | 177,595 | 192,107 | | | |
| | 5,776,257 | 5,660,082 | 3,616,498 | 3,606,420 | |
| Total Assets | 8,590,944 | 8,545,580 | 3,616,667 | 3,606,519 | |

UNAUDITED STATEMENTS OF FINANCIAL POSITION (cont'd)

| | Group | | Company | | |
|---|---------------------------------------|--|---------------------------------------|--|--|
| | As at 31/3/2019 <u>US\$'000</u> | As at 31/12/2018 <u>US\$'000</u> | As at 31/3/2019 <u>US\$'000</u> | As at 31/12/2018 <u>US\$'000</u> | |
| Liabilities and Equity | | | | | |
| Current Liabilities | | | | | |
| Short-term borrowings | 1,615,377 | 1,376,266 | - | - | |
| Bonds and notes payable | 124,757 | 124,640 | - | - | |
| Lease liabilities | 20,284 | - | - | - | |
| Trade payables | 651,042 | 683,349 | - | - | |
| Other payables (note(c)) | 313,291 | 287,748 | 51,102 | 40,789 | |
| Taxes payable | 15,457 | 18,899 | | | |
| | 2,740,208 | 2,490,902 | 51,102 | 40,789 | |
| Non-Current Liabilities | | | | | |
| Bonds and notes payables | 110,702 | 109,971 | - | - | |
| Long-term borrowings | 1,133,900 | 1,399,212 | - | - | |
| Lease liabilities | 23,050 | - | - | - | |
| Deferred tax liabilities | 76,274 | 78,080 | - | - | |
| Long-term payables and liabilities | 162,116 | 157,335 | _ | _ | |
| | 1,506,042 | 1,744,598 | - | | |
| | | | | | |
| Total Liabilities | 4,246,250 | 4,235,500 | 51,102 | 40,789 | |
| For the Arrest could be to O as a second than | 0 | | | | |
| Equity Attributable to Owners of the | | 200 000 | 200 000 | 200 020 | |
| Issued capital | 320,939 | 320,939 | 320,939 | 320,939 | |
| Share premium | 1,216,095 | 1,216,095 | 1,850,965 | 1,850,965 | |
| Treasury shares | (31,726) | (31,726) | (31,726) | (31,726) | |
| Other paid-in capital | 184,318 | 184,318 | - | - | |
| Other reserves | 24.474 | 04.474 | 24.474 | 04.474 | |
| Option reserve | 31,471 | 31,471 | 31,471 | 31,471 | |
| Currency translation reserve | (14,728) | (16,702) | - 1 | 4.040 | |
| Fair value reserve | 113,973 | 106,688 | 1,640 | 1,640 | |
| PRC statutory reserve | 3,820 | 3,820 | - | - | |
| Other reserve | 35,316 | 35,315 | | | |
| Datained accelera | 169,852 | 160,592 | 33,111 | 33,111 | |
| Retained earnings | 2,335,321 | 2,318,426 | 1,392,276 | 1,392,441 | |
| Non Controlling Interests | 4,194,799 | 4,168,644 | 3,565,565 | 3,565,730 | |
| Non-Controlling Interests | 149,895 | 141,436 | | 2 FGE 700 | |
| Total Equity | 4,344,694 | 4,310,080 | 3,565,565 | 3,565,730 | |
| Total Liabilities and Equity | 8,590,944 | 8,545,580 | 3,616,667 | 3,606,519 | |

UNAUDITED STATEMENTS OF FINANCIAL POSITION (cont'd)

Note:

(a) Other Current Assets

| | Group | | Com | pany |
|------------------------------------|-----------------|------------------|-----------------|------------------|
| | As at 31/3/2019 | As at 31/12/2018 | As at 31/3/2019 | As at 31/12/2018 |
| | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> |
| Prepaid expenses | 40,796 | 21,370 | 80 | 10 |
| Prepaid taxes | 109,431 | 117,481 | - | - |
| Deposits and advances to suppliers | 208,084 | 243,802 | - | - |
| Biological assets | 64,810 | 63,789 | - | - |
| Derivative receivable | 118,538 | 102,742 | - | - |
| Others | 151,121 | 152,546 | 1 | 1 |
| | 692,780 | 701,730 | 81 | 11 |
| Receivable from joint ventures | 70,956 | 68,230 | - | - |
| Receivable from related parties | 35,500 | 34,875 | | |
| | 799,236 | 804,835 | 81 | 11 |

(b)Long-Term Receivables and Assets

| | Group | | Com | pany |
|--------------------------------------|-----------------|------------------|-----------------|------------------|
| | As at 31/3/2019 | As at 31/12/2018 | As at 31/3/2019 | As at 31/12/2018 |
| | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> |
| Loan receivable from joint ventures | | | | |
| and an associated company | 81,677 | 80,793 | - | - |
| Tax recoverable | 175,086 | 204,729 | - | - |
| Advances for plasma plantations, net | 2,709 | 2,651 | - | - |
| Advances for projects | 20,556 | 12,290 | - | - |
| Land clearing | 1,835 | 1,894 | - | - |
| Advances for investment in land | 1,495 | 1,495 | - | - |
| Others | 20,035 | 19,673 | | |
| _ | 303,393 | 323,525 | | |

(c) Other Payables

| y canon rayables | Gr | Group | | pany |
|----------------------------|-----------------|------------------|-----------------|------------------|
| | As at 31/3/2019 | As at 31/12/2018 | As at 31/3/2019 | As at 31/12/2018 |
| | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> |
| Advances and deposits | 156,217 | 138,665 | - | - |
| Accrued expenses | 58,410 | 52,038 | 324 | 324 |
| Payable to third parties | 66,226 | 63,189 | - | - |
| Others | 28,009 | 30,251 | 7 | 7 |
| | 308,862 | 284,143 | 331 | 331 |
| Payable to related parties | 4,429 | 3,605 | 50,771 | 40,458 |
| | 313,291 | 287,748 | 51,102 | 40,789 |

1(b)(ii) Aggregate amount of group's borrowings and debt securities

| | A | us at 31/3/201 US\$'000 | 9 | Α | s at 31/12/20 ² US\$'000 | 18 |
|--|-----------|----------------------------|-----------|-----------|--|-----------|
| | Secured | Unsecured | Total | Secured | Unsecured | Total |
| Amount repayable in one year or less, or on demand | 1.000.305 | 760.113 | 1.760.418 | 847.888 | 653.018 | 1.500.906 |
| Amount repayable after | , , | | ,, - | - , | , | , , |
| one year | 983,253 | 284,399 | 1,267,652 | 1,219,203 | 289,980 | 1,509,183 |
| Total | 1,983,558 | 1,044,512 | 3,028,070 | 2,067,091 | 942,998 | 3,010,089 |

Details of any collateral

The secured borrowings are collaterised by certain cash and cash equivalents, short-term investments, inventories, trade receivables, bearer plants, biological assets, property, plant and equipment and right-of-use assets.

1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 31 MARCH 2019

| FOR THE PERIOD ENDED 31 MARCH 2019 | | |
|--|------------------------------------|------------------------------------|
| | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> |
| Cash flows from operating activities | | |
| Profit before tax | 33,746 | 17,432 |
| Adjustments for: | | |
| Net (gain)/loss from changes in fair value of biological assets | (1,021) | 811 |
| Depreciation | 75,050 | 70,731 |
| Amortisation | 1,245 | 700 |
| Unrealised foreign exchange gain | (1,388) | (5,654) |
| Share of results of associated companies, net of tax | (2,931) | 112 |
| Share of results of joint ventures, net of tax | 2,929 | 3,011 |
| (Gain)/Loss on disposal of property, plant and equipment | (137) | 473 |
| Bearer plants and property, plant and equipment written off | 267 | 221 |
| (Write-back of)/Allowance for impairment loss on: | | |
| Inventories, net | (199) | (4,209) |
| Trade receivables, net | 91 | 15 |
| Gain on disposal of a subsidiary | (11,449) | - |
| Changes in fair value of financial assets at fair value through profit or loss | 2,095 | 2,841 |
| Interest income | (5,800) | (9,238) |
| Interest expense | 41,275 | 36,533 |
| Operating cash flow before working capital changes | 133,773 | 113,779 |
| Changes in operating assets and liabilities: | | |
| Trade receivables | 7,503 | (41,465) |
| Other current assets | (9,781) | (151,189) |
| Inventories | 26,139 | (83,519) |
| Net assets for disposal group held for sale | - | 76,412 |
| Trade payables | 13,189 | 102,545 |
| Other payables | 36,595 | 9,432 |
| Cash generated from operations | 207,418 | 25,995 |
| Interest received | 3,622 | 7,904 |
| Interest paid | (45,024) | (37,010) |
| Tax refund/(paid) Net cash generated from/(used in) operating activities | 23,528 189,544 | (10,083) (13,194) |
| The cash generated from (used in) operating activities | 103,344 | (13,134) |

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS (cont'd) FOR THE PERIOD ENDED 31 MARCH 2019

| | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> |
|--|------------------------------------|------------------------------------|
| Cash flows from investing activities | | |
| Proceeds from disposal of property, plant and equipment | 7,955 | 4,490 |
| Proceeds from disposal of bearer plants | 285 | 280 |
| Capital expenditure on property, plant and equipment | (56,730) | (39,754) |
| Capital expenditure on bearer plants | (7,304) | (4,728) |
| Investment in financial assets, net | (60,172) | (101,375) |
| Investment in an associated company | - | (1,164) |
| Investments in Plasma/KKPA Program plantations, net | (19) | (818) |
| Dividend received from a joint venture | - | 4,743 |
| Payments for deferred expenditure and intangible assets | (4,160) | (1,471) |
| Net (increase)/decrease in long-term receivables and assets | (9,627) | 1,373 |
| Net cash used in investing activities | (129,772) | (138,424) |
| Cash flows from financing activities | | |
| Proceeds from short-term borrowings | 1,038,103 | 1,357,647 |
| Proceeds from long-term borrowings | 55,671 | 161,500 |
| Payments of short-term borrowings | (816,987) | (1,359,915) |
| Payments of long-term borrowings | (300,797) | (147,597) |
| Proceeds from notes issue | - | 112,613 |
| Payments of principal element of leases | (5,253) | - |
| Payments of deferred loan charges and bank loan administration costs | (1,387) | (1,073) |
| Decrease in cash in banks and time deposits pledged | 16,994 | 20,841 |
| Net cash (used in)/generated from financing activities | (13,656) | 144,016 |
| | | |
| Net increase/(decrease) in cash and cash equivalents | 46,116 | (7,602) |
| Cash and cash equivalents at the beginning of the period | 158,747 | 127,198 |
| Cash and cash equivalents at the end of the period (See Note below) | 204,863 | 119,596 |
| • | | |

Note:

Cash and cash equivalents included in consolidated statement of cash flows consist of the following:

| | 31/3/2019 <u>US\$'000</u> | 31/3/2018 <u>US\$'000</u> |
|---|------------------------------|------------------------------|
| Time deposits, cash and bank balances | 221,888 | 117,979 |
| Less: Cash in banks and time deposits pledged | (17,025) | (12,412) |
| | 204,863 | 105,567 |
| Cash and bank balances included in disposal group held for sale | | 14,029 |
| | 204,863 | 119,596 |

1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

| | < | | Attributable | e to Owners Other | of the Com | pany | > | Non- | |
|--|-------------------|------------------|--------------------|----------------------|-------------------|----------------------|-----------------|--------------------------|-----------------|
| The Group | Issued Capital | Share Premium | Treasury Shares | Paid-in Capital | Other Reserves | Retained Earnings | Total | Controlling Interests | Total Equity |
| | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> |
| Balance at 31 Dec 2018 | 320,939 | 1,216,095 | (31,726) | 184,318 | 160,592 | 2,318,426 | 4,168,644 | 141,436 | 4,310,080 |
| Effect of adoption of IFRS 16 | - | - | - | - | - | (1,419) | (1,419) | - | (1,419) |
| Balance at 1 Jan 2019 | 320,939 | 1,216,095 | (31,726) | 184,318 | 160,592 | 2,317,007 | 4,167,225 | 141,436 | 4,308,661 |
| Profit for the period | - | - | - | - | - | 18,314 | 18,314 | 7,808 | 26,122 |
| Other comprehensive income | - | - | - | - | 9,260 | - | 9,260 | 651 | 9,911 |
| Total comprehensive income for the period | - | - | - | - | 9,260 | 18,314 | 27,574 | 8,459 | 36,033 |
| Balance at 31 Mar 2019 | 320,939 | 1,216,095 | (31,726) | 184,318 | 169,852 | 2,335,321 | 4,194,799 | 149,895 | 4,344,694 |
| Balance at 1 Jan 2018 as previously announced | 320,939 | 1,216,095 | (31,726) | 184,318 | 51,055 | 2,265,011 | 4,005,692 | 101,570 | 4,107,262 |
| Profit for the period | - | - | - | - | - | 11,851 | 11,851 | 1,579 | 13,430 |
| Other comprehensive income/(loss) | - | - | - | - | 447 | - | 447 | (449) | (2) |
| Total comprehensive income for the period | - | - | - | - | 447 | 11,851 | 12,298 | 1,130 | 13,428 |
| Balance at 31 Mar 2018 | 320,939 | 1,216,095 | (31,726) | 184,318 | 51,502 | 2,276,862 | 4,017,990 | 102,700 | 4,120,690 |

1(d) (i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year

| The Company | Issued Capital US\$'000 | Share Premium US\$'000 | Treasury Shares US\$'000 | Other Reserves US\$'000 | Retained Earnings US\$'000 | Total US\$'000 |
|--|-------------------------------|------------------------------|--------------------------|-------------------------------|----------------------------------|-------------------|
| Balance at 1 Jan 2019 | 320,939 | 1,850,965 | (31,726) | 33,111 | 1,392,441 | 3,565,730 |
| Loss for the period, representing total comprehensive loss for the period | - | - | _ | | (165) | (165) |
| Balance at 31 Mar 2019 | 320,939 | 1,850,965 | (31,726) | 33,111 | 1,392,276 | 3,565,565 |
| Balance at 1 Jan 2018 as previously announced Loss for the period, representing total comprehensive loss for the | 320,939 | 1,850,965 | (31,726) | 31,471 | 48,203 (126) | 2,219,852 |
| period Balance at 31 Mar 2018 | 320,939 | 1,850,965 | (31,726) | 31,471 | 48,077 | 2,219,726 |

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, as well as the number of shares held as treasury shares, if any, against the total number of issued shares excluding treasury shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year

Details of the Company's issued and paid-up capital were as follows:

Number/Percentage of treasury shares

Number of issued shares (excluding treasury shares)

| As at | | | | |
|--------------------|--------------------|--|--|--|
| 31 Mar 2019 | 31 Dec 2018 | | | |
| 102,792,400 / 0.8% | 102,792,400 / 0.8% | | | |
| 12,734,756,156 | 12,734,756,156 | | | |

There were no movements in the Company's issued share capital (excluding treasury shares) since 31 December 2018.

1(d)(iii) To show the number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

The total number of issued shares excluding treasury shares as at 31 March 2019 and 31 December 2018 respectively was 12,734,756,156 ordinary shares.

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

There were no changes in the number of ordinary shares held as treasury shares by the Company since 31 December 2018.

2. Whether the figures have been audited, or reviewed and in accordance with which auditing standard or practice

These figures have not been audited, or reviewed by the auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of matter)

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied

Except as disclosed in Note 5 below, the Group has applied the same accounting policies and methods of computation consistent with those used in the most recent audited annual financial statements for the year ended 31 December 2018.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change

The Group adopted various new and revised IFRSs that are relevant to its operations and effective for period beginning 1 January 2018. Except as disclosed below, the adoption of the new and revised IFRSs has had no material financial impact on the Group's financial statements.

IFRS 16, *Leases* sets out a revised framework for the recognition, measurement, presentation and disclosure of leases, and replaces existing lease accounting guidance. IFRS 16 requires lessees to recognise right-of-use assets and lease liabilities for all leases with a term of more than 12 months, except where the underlying asset is of low value. The right-of-use asset is depreciated and interest expense is recognised on the lease liability. The accounting requirements for lessors have not been changed substantially, and continue to be based on classification as operating and finance leases. Disclosure requirements have been enhanced for both lessors and lessees.

The Group plans to adopt IFRS 16 on 1 January 2019 based on a permitted transition approach that does not restate comparative information, but recognises the cumulative effect of initially applying SFRS(I) 16 as an adjustment to the opening balance of retained earnings on 1 January 2019. The Group also plans to adopt an expedient offered by IFRS 16, exempting the Group from having to reassess whether pre-existing contracts contain a lease.

The Group has entered into leasing arrangements with lessors for rental of office premises and properties as lessee. Prior to adoption of IFRS 16, the Group recognised these arrangement as operating leases and payments made under operating leases are recognised in the income statement on a straight-line basis over the period of the lease. Upon adoption of IFRS 16, the Group recognised the right-of-use assets and lease liabilities. The nature of expenses related to those leases will change as IFRS 16 replaces the straight-line operating lease expense with depreciation charge for right-of-use assets and interest expenses on lease liabilities. The Group does not restate the comparative information for the effect of adopting IFRS 16 due to the exemption in IFRS 16 but has instead recognised the effect in retained earnings and other reserves as at 1 January 2019.

The following reconciliations summaries the impacts of transition to IFRS 16 on the Group's financial statements.

Consolidated statement of financial position as at 31 December 2018 and 1 January 2019

| | At 31 Dec 2018 US\$'000 | Effect of IFRS 16 US\$'000 | At 1 Jan 2019 US\$'000 |
|---|----------------------------|-------------------------------|---------------------------|
| Right-of-use assets Lease liabilities: | - | 46,685 | 46,685 |
| Current | - | (21,228) | (21,228) |
| Non-current | - | (26,876) | (26,876) |
| Retained earnings | 2,318,426 | (1,419) | 2,317,007 |

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

Earnings per ordinary share for the period after deducting any provision for preference dividends:-

- (i) Based on weighted average number of shares
 - Weighted average number of shares
- (ii) On a fully diluted basis

| The Group | | | | |
|----------------|----------------|--|--|--|
| 1st Qtr | 1st Qtr | | | |
| 2019 | 2018 | | | |
| | | | | |
| USD0.14cents | USD0.09cents | | | |
| 12,734,756,156 | 12,734,756,156 | | | |
| Not applicable | Not applicable | | | |

 Net asset value (for the issuer and group) per ordinary share based on issued shares excluding treasury shares of the issuer at the end of the (a) current financial period reported on and (b) immediately preceding financial year

Net asset value per ordinary share based on existing issued share capital of 12,734,756,156 shares

| The | Group | The Company | | |
|-------------------|----------------------|----------------------|----------------------|--|
| As at 31 Mar 2019 | As at 31 Dec 2018 | As at 31 Mar 2019 | As at 31 Dec 2018 | |
| US\$0.33 | US\$0.33 | US\$0.28 | US\$0.28 | |

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

| Revenue by segment | 1st Qtr 2019 <u>US\$'000</u> | 1st Qtr 2018 <u>US\$'000</u> | Change <u>%</u> |
|--------------------------------|---------------------------------|---------------------------------|--------------------|
| Plantations and palm oil mills | 307,808 | 342,822 | (10.2) |
| Palm, laurics and others | 1,609,658 | 1,804,752 | (10.8) |
| Inter-segment eliminations | (300,171) | (331,402) | (9.4) |
| Total Revenue | 1,617,295 | 1,816,172 | (11.0) |
| EBITDA by segment | | | |
| Plantations and palm oil mills | 60,800 | 94,834 | (35.9) |
| Palm, laurics and others | 59,333 | 28,014 | 111.8 |
| Inter-segment eliminations | 506 | (1,714) | n.m. |
| Total EBITDA | 120,639 | 121,134 | (0.4) |

Notes:

- (1) EBITDA refers to earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net gain/(loss) from changes in fair value of biological assets, foreign exchange gain and exceptional item.
- (2) Plantations and palm oil mills segment refers to products from upstream business.
- (3) Palm, laurics and others segment refers to processing and merchandising of palm and oilseed based products i.e. bulk, branded, oleo-chemicals and other vegetable oils, as well as production and distribution of other consumer products in China and Indonesia mainly food and beverages.

REVIEW OF PERFORMANCE FOR THREE MONTHS ENDED 31 MARCH 2019

The Group recorded lower revenue of US\$1,617.3 million for the three months ended 31 March 2019 ("1Q2019") as compared to US\$1,816.2 million in the corresponding period in 2018 ("1Q2018") mainly due to softer crude palm oil ("CPO") prices. Despite lower revenue, EBITDA of the Group remained constant at US\$120.6 million in 1Q2019 mainly attributable to better performance of our palm, laurics and others segment.

PLANTATIONS AND PALM OIL MILLS

Revenue from our plantation and palm oil mills segment decreased by 10.2% to US\$307.8 million in 1Q2019. This was mainly attributable to the lower CPO prices during the current period, partially offset by the higher sales volume. The average international CPO (FOB Belawan) price for the current period was 20.6% lower at US\$512 per tonne as compared to US\$645 per tonne in 1Q2018. Consequently, EBITDA from our plantations and palm oil mills segment decreased by 35.9% to US\$60.8 million in 1Q2019.

Fresh fruit bunch ("FFB") and total palm product output for the current period were higher at 2,174,000 tonnes and 629,000 tonnes respectively as compared to 2,125,000 tonnes and 612,000 tonnes respectively in 1Q2018.

PALM, LAURICS AND OTHERS

Our palm, laurics and others segment refers to all processing and merchandising of palm and oilseeds product, oleo-chemicals and other vegetable oils, as well as production and distribution of other consumer products in China and food and beverages in Indonesia. Revenue from this segment was lower by 10.8% to US\$1,609.7 million in 1Q2019. This was mainly attributable to lower CPO prices and lower sales volume for oilseeds in China, which was offset by the strong demand for biodiesel in Indonesia. Despite lower prices, EBITDA increased from US\$28.0 million in 1Q2018 to US\$59.3 million in the current period with higher EBITDA margin due to additional contribution from biodiesel and the removal of export levy in Indonesia.

FINANCIAL EXPENSES, NET

Net financial expenses comprised net interest expenses (after deducting interest income), amortisation of deferred loan charges and other finance charges. Net financial expenses increased from US\$28.0 million in 1Q2018 to US\$36.0 million in the current period mainly due to higher borrowing cost which is in line with higher interest rate and higher average total borrowings in the current year.

FOREIGN EXCHANGE GAIN, NET

Net foreign exchange gain was higher at US\$18.2 million in 1Q2019 as compared to US\$5.1 million in 1Q2018. The current period's gain was mainly attributable to fair value gain on forward foreign currency contracts entered to hedge the currency exposure during the current period.

OTHER OPERATING INCOME

Net other operating income comprised mainly changes in fair value of biological assets (agricultural produce) and financial assets, income from sales of seedlings and other materials, as well as rental income. The Group recorded higher net other operating income of US\$8.4 million in the current period mainly due to higher gain from disposal of other material and by-products and gain from changes in fair value of biological assets

EXCEPTIONAL ITEM

Exceptional item in the current period related to gain on disposal of a subsidiary in Indonesia.

TAX

Income tax comprised provision for current and deferred income tax derived by applying the varying statutory tax rates of the different countries in which the Group operates on its taxable profit and taxable temporary difference. No group relief is available for set-off of taxable profits against tax losses of companies within the Group. Net tax expense increased from US\$4.0 million to US\$7.6 million in 1Q2019 mainly due to higher deferred tax expenses as compared to deferred tax income in 1Q2018.

REVIEW OF FINANCIAL POSITION AS AT 31 MARCH 2019

The Group adopted IFRS 16, *Leases*, requiring lessees to recognise right-of-use assets and lease liabilities for all leases with effect from 1 January 2019. The cumulative effect of initial application has been adjusted against the opening balance of retained earnings on 1 January 2019 based on the permitted transition approach. Details and impact of adjustment are disclosed in Note 5 above.

ASSETS

The Group's total assets increased from US\$8,545.6 million as at end 2018 to US\$8,590.9 million as at 31 March 2019. This increase was mainly due to recognition of right-of-use assets and additional investments in logistics and technology related investments, partially offset with lower trade receivables.

LIABILITIES

Total liabilities of the Group increased from US\$4,235.5 million as at end 2018 to US\$4,246.3 million as at 31 March 2019. This was mainly attributable to recognition of lease liabilities and increase in advances and deposits received from customers, partially offset with lower trade payables.

REVIEW OF CASH FLOWS FOR THREE MONTHS ENDED 31 MARCH 2019

The Group recorded a net cash inflow for its operating activities (after payment of taxes and interest expenses) of US\$189.5 million in 1Q2019 as compared to a net cash outflow in the previous corresponding period. This was mainly due to better operating results and lower working capital requirement for our downstream activities.

Net cash used in investing activities of US\$129.8 million was mainly related to capital expenditures on our property, plant and equipment, and additional investment in long-term investments.

Net cash used in financing activities of US\$13.7 million was mainly related to repayment of borrowings (net of proceeds) during the current period.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable.

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

Weather conditions, supply and demand for CPO and other competing seed oils, and developments in government policy of the countries we operate in or trade with will continue to have an impact on the prices for commodities including CPO. We expect the demand growth for CPO to remain stable underpinned by global food and energy demand, particularly the increase in biodiesel consumption in Indonesia. However, given the increasing supply of CPO, the price of CPO is expected to be rangebound.

The Group will continue to enhance its integrated operation capabilities in an efficient and innovative way, so as to optimise profit opportunities across the value chain, as well as to improve its yield, cost efficiency and sustainability initiatives.

11. Dividend

(a) Current Financial Period Reported On

Any ordinary dividend declared for the current financial period reported on? No.

(b) Corresponding Period of the Immediately Preceding Financial Year

Any ordinary dividend declared for the corresponding period of the immediately preceding financial year? No.

(c) Date payable

Not applicable.

(d) Books closure date

Not applicable.

12. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision

No dividend has been declared for the quarter ended 31 March 2019 as the Company generally review its dividend distribution during the second half of the financial year.

13. Interested persons transactions disclosure

| Name of interested person | Aggregate value of all interested person transactions during the period under review (excluding transactions less than SGD100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920) | Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than SGD100,000) |
|--------------------------------|--|--|
| | US\$ | US\$ |
| PT Asuransi Sinar Mas | - | 193,555 |
| PT Bank Sinarmas Tbk | - | 4,886,286* |
| PT Cakrawala Mega Indah | - | 21,438,090 |
| PT Golden Energy Mines Tbk | - | 599,659 |
| PT Maritim Sinar Utama | - | 672,267 |
| PT Rolimex Kimia Nusamas | - | 2,738,510 |
| PT Roundhill Capital Indonesia | - | 2,272,078 |
| PT Sinar Jati Mitra | - | 476,772 |
| PT Sinar Mas Tjipta | - | 770,000 |
| Total | - | 34,047,217 |

Note:

PART II - ADDITIONAL INFORMATION REQUIRED FOR FULL YEAR ANNOUNCEMENT

14. Segmented revenue and results for business or geographical segments (of the group) in the form presented in the issuer's most recently audited annual financial statements, with comparative information for the immediately preceding year

Not applicable.

15. In the review of performance, the factors leading to any material changes in contributions to turnover and earnings by the business or geographical segments

Not applicable.

16. A breakdown of sales

Not applicable.

^{*} Principal amount of placements as at 31 March 2019 is approximately US\$4.89 million.

17. A breakdown of the total annual dividend (in dollar value) for the issuer's latest full year and its previous full year

Not applicable.

18. Confirmation pursuant to the Rule 705(5) of the listing manual

We, Franky Oesman Widjaja and Rafael Buhay Concepcion, Jr., being two directors of Golden Agri-Resources Ltd (the "Company"), do hereby confirm on behalf of the directors of the Company that, to the best of their knowledge, nothing has come to their attention which would render the first quarter ended 31 March 2019 unaudited financial results to be false or misleading.

On behalf of the board of directors

Franky Oesman Widjaja Director Rafael Buhay Concepcion, Jr. Director

19. Confirmation pursuant to the Rule 720(1) of the listing manual

The Company confirms that it has procured undertakings from all its directors and executive officers in the form set out in Appendix 7.7 under Rule 720(1) of the Listing Manual.

BY ORDER OF THE BOARD

Rafael Buhay Concepcion, Jr. Director 14 May 2019

Submitted by Kimberley Lye Chor Mei, Director, Corporate Secretarial on 14 May 2019 to the SGX